Jacobs Levy Equity Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Jacobs Levy Equity Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-384,168	Closed	-$11.2M	–	1122
2021 Q4	$11.2M	Buy	384,168 +86,117	+29%	+$2.67M	0.08%	278
2021 Q3	$7.59M	Buy	298,051 +172,956	+138%	+$5.08M	0.05%	356
2021 Q2	$4.38M	Sell	125,095 -7,445	-6%	-$291K	0.03%	458
2021 Q1	$5.4M	Sell	132,540 -31,980	-19%	-$1.47M	0.04%	406
2020 Q4	$7.13M	Buy	164,520 +155,013	+1,631%	+$7.64M	0.06%	330
2020 Q3	$524K	Buy	+9,507	New	+$604K	0.01%	783
2016 Q2	–	Sell	-28,300	Closed	-$449K	–	1255
2016 Q1	$449K	Buy	+28,300	New	+$503K	0.01%	750

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jacobs Levy Equity Management's GBT Position: Q1 2022 in Review

Jacobs Levy Equity Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2022, closing a stake of 384,168 shares — an estimated $11.2M sold.

Jacobs Levy Equity Management first reported a position in GBT in Q1 2016 and held it in 7 quarters. The position peaked at $11.2M in Q4 2021. 204 funds tracked by Wall St. Rank hold GBT as of Q1 2022.

Jacobs Levy Equity Management reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
Jacobs Levy Equity Management sold 384,168 Global Blood Therapeutics, Inc. shares in Q1 2022, an estimated $11.2M.
Jacobs Levy Equity Management first reported a position in Global Blood Therapeutics, Inc. in Q1 2016 and held it in 7 quarters.
Jacobs Levy Equity Management's Global Blood Therapeutics, Inc. position peaked at $11.2M in Q4 2021.
204 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2022, filed 16 May 2022.